MedTrace Logo

Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder

NCT01614041 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 274

Last updated 2020-01-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of comparative high dose Tandospirone Citrate in the treatment of patients with generalized anxiety disorder.

Conditions

  • Generalized Anxiety Disorder

Interventions

DRUG

Usual dose treatment of Tandospirone

Usual dose treatment of Tandospirone, oral, 30 mg/day

DRUG

Comparative high dose of tandospirone treatment

Comparative high dose of tandospirone treatment, oral, 60 mg/day

Sponsors & Collaborators

  • Sumitomo Pharma (Suzhou) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Wenyuan Wu, MD · Shanghai Tongji Hospital, Tongji University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-10
Primary Completion
2018-09-11
Completion
2019-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01614041 on ClinicalTrials.gov